Abstract 265O
Background
Anlotinib is a novel multikinase inhibitor targeting VEGFR, PDGFR, FGFR, and c-Kit. This study investigated the potency of anlotinib in treating locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC).
Methods
This is a randomized, double-blind, placebo-controlled, multicenter phase II trial (NCT02586337). Eligible pts were 18-70 years old with measurable, pathologically confirmed locally advanced or metastatic RAIR-DTC. Pts who had received previous anlotinib or other VEGFR-TKIs were excluded. Pts were randomized in a 2:1 ratio to receive anlotinib or placebo with a dose of 12mg QD for 2 weeks followed by a week of rest (2/1 schedule). The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. Pts in placebo arm were allowed to receive open-label anlotinib after disease progression.
Results
Between September 2015 and August 2018, 113 pts (76 in anlotinib arm and 37 in placebo arm) were enrolled. The data cutoff date for primary endpoint was January 1, 2020. The research met its primary endpoint that the median PFS was 40.54 months (95% CI 28.29, NE) in anlotinib arm and 8.38 months (95% CI 5.59, 13.80) in placebo arm (p < 0.0001). The HR was 0.21 (95% CI 0.12, 0.37). The ORR was 59.21% in anlotinib arm and no response was observed in placebo arm (p < 0.0001). In addition, significant DCR benefit was observed for anlotinib treatment (anlotinib arm vs. placebo arm = 97.37% vs. 78.38%, p = 0.002). The OS data was still in follow-up. All pts in anlotinib arm and 97.30% pts in placebo arm experienced adverse events (p = 0.327). The incidence of treatment-related AEs of two groups was 100.00% and 86.49% (p = 0.003). Serious treatment-related AEs occurred in 15.79% pts received anlotinib. The most common AEs in anlotinib arm were hypertension (84.21%) and hypertriglyceridemia (68.42%).
Conclusions
The study demonstrates the efficacy and safety of anlotinib and supports its use as a new option for the treatment of locally advanced or metastatic RAIR-DTC.
Clinical trial identification
NCT02586337.
Editorial acknowledgement
Legal entity responsible for the study
Chia Tai TianQing Pharmaceutical Group Co., Ltd.
Funding
Chia Tai TianQing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
266O - Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939
Presenter: Hsiang-Fong Kao
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
267O - Distinct phenotypes of locoregionally advanced (LA-NPC) harbor disparate survival outcomes and are associated with germline variants
Presenter: Enya Ong
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
268MO - A phase-Ib study of lucitanib (AL3810) in a cohort of patients with recurrent and metastatic nasopharyngeal carcinoma (NPC)
Presenter: Hong-yun Zhao
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
269MO - Comparison of three induction chemotherapy regimens with gemcitabine plus cisplatin, cisplatin plus fluorouracil, and cisplatin plus capecitabine for locoregionally advanced nasopharyngeal carcinoma: A pooled analysis of two prospective studies
Presenter: Sik Kwan Chan
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
270MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Presenter: Li Zhang
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 265O, 266O and 267O
Presenter: Ingeborg Tinhofer-Keilholz
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Slides
Webcast
Invited Discussant abstracts 268MO, 269MO and 270MO
Presenter: Edwin Hui
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Amanda Psyrri
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Webcast
LIVE Q&A
Presenter: Amanda Psyrri
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Webcast